Inspire Investing’s Esperion Therapeutics ESPR Stock Holding History

Inspire Investing’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-341,223	Closed	-$758K	–	851
2024 Q2	$758K	Buy	+341,223	New	+$803K	0.09%	272

Other funds holding ESPR

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Inspire Investing's ESPR Position: Q3 2024 in Review

Inspire Investing sold out of Esperion Therapeutics (ESPR) in Q3 2024, closing a stake of 341,223 shares — an estimated $758K sold.

Inspire Investing first reported a position in ESPR in Q2 2024 and held it in 1 quarter. The position peaked at $758K in Q2 2024. 183 funds tracked by Wall St. Rank hold ESPR as of Q3 2024.

Inspire Investing reported no remaining Esperion Therapeutics position as of Q3 2024 after selling out during the quarter.
Inspire Investing sold 341,223 Esperion Therapeutics shares in Q3 2024, an estimated $758K.
Inspire Investing first reported a position in Esperion Therapeutics in Q2 2024 and held it in 1 quarter.
Inspire Investing's Esperion Therapeutics position peaked at $758K in Q2 2024.
183 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2024.

Based on Inspire Investing's 13F filing for Q3 2024, filed 10 Oct 2024.